(Q51646044)

8 April 2018

title

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. (English)

1 reference

8 April 2018

1 reference

1

Pier Luigi Zinzani

1 reference

8 April 2018

Enrico Derenzini

object named as

Enrico Derenzini

8

0 references

Michele Baccarani

10

object named as

Michele Baccarani

1 reference

8 April 2018

Letizia Gandolfi

2

1 reference

8 April 2018

Alessandro Broccoli

3

1 reference

8 April 2018

Lisa Argnani

4

1 reference

8 April 2018

Stefano Fanti

5

1 reference

8 April 2018

Cinzia Pellegrini

6

1 reference

8 April 2018

Vittorio Stefoni

7

1 reference

8 April 2018

Federica Quirini

9

1 reference

8 April 2018

language of work or name

English

0 references

publication date

19 October 2010

1 reference

8 April 2018

published in

Cancer

1 reference

8 April 2018

volume

117

1 reference

8 April 2018

issue

5

1 reference

8 April 2018

page(s)

1010-1018

1 reference

8 April 2018

PET/CT for therapy response assessment in lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

The case against heavy PETing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

7 January 2021

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

7 January 2021

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

7 January 2021

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25579

7 January 2021

Identifiers

DOI

10.1002/CNCR.25579

1 reference

8 April 2018

PubMed ID

20960498

1 reference

8 April 2018